Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
Karmali
Mohamed A
MA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004927:Escherichia coli Infections / Q000150:complications / Q000517:prevention & control*; D019453:Escherichia coli O157 / Q000378:metabolism / Q000472:pathogenicity*; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D051379:Mice; D018716:Molecular Mimicry; D011108:Polymers / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D014281:Trihexosylceramides / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D011108:Polymers; D011956:Receptors, Cell Surface; D014281:Trihexosylceramides; C018549:globotriaosylceramide